Computational design and discovery of "minimally structured" hERG blockers

Journal of Medicinal Chemistry

Volumn 55, Issue 8, 2012, Pages 4010-4014

  Cavalli, Andrea ^a,b   Buonfiglio, Rosa ^a   Ianni, Cristina ^a   Masetti, Matteo ^a   Ceccarini, Luisa ^a   Caves, Rachel ^c   Chang, Michael W Y ^c   Mitcheson, John S ^c   Roberti, Marinella ^a   Recanatini, Maurizio ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b ISTITUTO ITALIANO DI TECNOLOGIA   (Italy)

^c UNIVERSITY OF LEICESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

POTASSIUM CHANNEL BLOCKING AGENT; POTASSIUM CHANNEL HERG;

ARTICLE; COMPUTATIONAL FLUID DYNAMICS; DRUG DESIGN; DRUG SCREENING; DRUG SYNTHESIS; IC 50; PROCESS OPTIMIZATION; STUDY DESIGN;

DRUG DESIGN; ETHER-A-GO-GO POTASSIUM CHANNELS; HUMANS; LONG QT SYNDROME; POTASSIUM CHANNEL BLOCKERS; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84860310064     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm201194q     Document Type: Article

References (29)

1. Sanguinetti, M. C.; Tristani-Firouzi, M. hERG potassium channels and cardiac arrhythmia Nature 2006, 440, 463-469
2. Shah, R. R. Can pharmacogenetics help rescue drugs withdrawn from the market? Pharmacogenomics 2006, 7, 889-908 (Pubitemid 44446737)
3. + channel HERG Mol. Pharmacol. 2001, 59, 122-126 (Pubitemid 32043093)
4. Bischoff, U.; Schmidt, C.; Netzer, R.; Pongs, O. Effects of fluoroquinolones on HERG currents Eur. J. Pharmacol. 2000, 406, 341-343
5. + channel block-related cardiotoxicity by the H1 receptor blocker cetirizine compared with other second-generation antihistamines Mol. Pharmacol. 1998, 54, 113-121 (Pubitemid 28337593)
6. Suessbrich, H.; Schonherr, R.; Heinemann, S. H.; Attali, B.; Lang, F.; Busch, A. E. The inhibitory effect of the antipsychotic drug haloperidol on HERG potassium channels expressed in Xenopus oocytes Br. J. Pharmacol. 1997, 120, 968-974 (Pubitemid 27122740)
7. Suessbrich, H.; Waldegger, S.; Lang, F.; Busch, A. E. Blockade of HERG channels expressed in Xenopus oocytes by the histamine receptor antagonists terfenadine and astemizole FEBS Lett. 1996, 385, 77-80 (Pubitemid 26153472)
8. Stork, D.; Timin, E. N.; Berjukow, S.; Huber, C.; Hohaus, A.; Auer, M.; Hering, S. State dependent dissociation of HERG channel inhibitors Br. J. Pharmacol. 2007, 151, 1368-1376 (Pubitemid 47255915)
9. Recanatini, M.; Cavalli, A.; Masetti, M. Modeling HERG and its interactions with drugs: recent advances in light of current potassium channel simulations ChemMedChem 2008, 3, 523-535
10. Raschi, E.; Ceccarini, L.; De Ponti, F.; Recanatini, M. hERG-related drug toxicity and models for predicting hERG liability and QT prolongation Expert Opin. Drug Metab. Toxicol. 2009, 5, 1005-1021
11. Ekins, S.; Crumb, W. J.; Sarazan, R. D.; Wikel, J. H.; Wrighton, S. A. Three-dimensional quantitative structure-activity relationship for inhibition of human ether-a-go-go-related gene potassium channel J. Pharmacol. Exp. Ther. 2002, 301, 427-434 (Pubitemid 34429951)
12. Cavalli, A.; Poluzzi, E.; De Ponti, F.; Recanatini, M. Toward a pharmacophore for drugs inducing the long QT syndrome: insights from a CoMFA study of HERG K(+) channel blockers J. Med. Chem. 2002, 45, 3844-3853 (Pubitemid 35024289)
13. + channel blockers Bioorg. Med. Chem. 2004, 12, 2307-2315 (Pubitemid 38471715)
14. Pearlstein, R. A.; Vaz, R. J.; Kang, J.; Chen, X. L.; Preobrazhenskaya, M.; Shchekotikhin, A. E.; Korolev, A. M.; Lysenkova, L. N.; Miroshnikova, O. V.; Hendrix, J.; Rampe, D. Characterization of HERG potassium channel inhibition using CoMSiA 3D QSAR and homology modeling approaches Bioorg. Med. Chem. Lett. 2003, 13, 1829-1835 (Pubitemid 36561175)
15. Aronov, A. M. Common pharmacophores for uncharged human ether-a-go-go-related gene (hERG) blockers J. Med. Chem. 2006, 49, 6917-6921 (Pubitemid 44749757)
16. Thai, K. M.; Ecker, G. F. A binary QSAR model for classification of hERG potassium channel blockers Bioorg. Med. Chem. 2008, 16, 4107-4119 (Pubitemid 351484009)
17. Nisius, B.; Goller, A. H.; Bajorath, J. Combining cluster analysis, feature selection and multiple support vector machine models for the identification of human ether-a-go-go related gene channel blocking compounds Chem. Biol. Drug Des. 2009, 73, 17-25
18. Doddareddy, M. R.; Klaasse, E. C.; Shagufta; Ijzerman, A. P.; Bender, A. Prospective validation of a comprehensive in silico hERG model and its applications to commercial compound and drug databases ChemMedChem 2010, 5, 716-729
19. Gavaghan, C.; Arnby, C.; Blomberg, N.; Strandlund, G.; Boyer, S. Development, interpretation and temporal evaluation of a global QSAR of hERG electrophysiology screening data J. Comput.-Aided Mol. Des. 2007, 21, 189-206 (Pubitemid 46510843)
20. Pollard, C. E.; Abi Gerges, N.; Bridgland-Taylor, M. H.; Easter, A.; Hammond, T. G.; Valentin, J. P. An introduction to QT interval prolongation and non-clinical approaches to assessing and reducing risk Br. J. Pharmacol. 2010, 159, 12-21
21. + channel using docking and molecular dynamics methods FEBS Lett. 2005, 579, 2939-2944 (Pubitemid 40725270)
22. Stansfeld, P. J.; Gedeck, P.; Gosling, M.; Cox, B.; Mitcheson, J. S.; Sutcliffe, M. J. Drug block of the hERG potassium channel: insight from modeling Proteins 2007, 68, 568-580 (Pubitemid 46981949)
23. Masetti, M.; Cavalli, A.; Recanatini, M. Modeling the hERG potassium channel in a phospholipid bilayer: molecular dynamics and drug docking studies J. Comput. Chem. 2008, 29, 795-808 (Pubitemid 351364854)
24. Cramer, R. D.; Patterson, D. E.; Bunce, J. D. Comparative molecular field analysis (CoMFA). 1. Effect of shape on binding of steroids to carrier proteins J. Am. Chem. Soc. 1988, 110, 5959-5967
25. Mitcheson, J. S.; Chen, J.; Lin, M.; Culberson, C.; Sanguinetti, M. C. A structural basis for drug-induced long QT syndrome Proc. Natl. Acad. Sci. U.S.A. 2000, 97, 12329-12333
26. Fernandez, D.; Ghanta, A.; Kauffman, G. W.; Sanguinetti, M. C. Physicochemical features of the HERG channel drug binding site J. Biol. Chem. 2004, 279, 10120-10127 (Pubitemid 38372616)
27. Tilley, J. W.; Levitan, P.; Welton, A. F.; Crowley, H. J. Antagonists of slow-reacting substance of anaphylaxis. 1. Pyrido[2,1- b ]quinazolinecarboxylic acid derivatives J. Med. Chem. 1983, 26, 1638-1642 (Pubitemid 14245359)
28. Wise, L. D.; Pattison, I. C.; Butler, D. E.; DeWald, H. A.; Lewis, E. P.; Lobbestael, S. J.; Nordin, I. C.; Poschel, B. P.; Coughenour, L. L. 1-[3-(Diarylamino)propyl]piperidines and related compounds, potential antipsychotic agents with low cataleptogenic profiles J. Med. Chem. 1985, 28, 606-612 (Pubitemid 15098166)
29. Perry, M.; Stansfeld, P. J.; Leaney, J.; Wood, C.; de Groot, M. J.; Leishman, D.; Sutcliffe, M. J.; Mitcheson, J. S. Drug binding interactions in the inner cavity of HERG channels: molecular insights from structure-activity relationships of clofilium and ibutilide analogs Mol. Pharmacol. 2006, 69, 509-519 (Pubitemid 43121948)